Percutaneous right ventricular assist device in sepsis due to right ventricular failure and pulmonary hypertension

Hansen, Lars Nikolaj; Berg, H.; Schmidt, Henrik; Veien, Karsten Tange; Jensen, M.; Junker, Anders; Møller, Jacob Eifer

doi:10.1111/aas.12776

Cited by 4 publications

(3 citation statements)

References 9 publications

(11 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This patient showed hemodynamic improvement and was weaned from the device but died a couple of days later from gastrointestinal bleeding. 24…”

Section: Microaxial Flow Pumpsmentioning

confidence: 99%

Extracorporeal Life Support in Pulmonary Hypertension: Practical Aspects

Hoeper

2023

Semin Respir Crit Care Med

View full text Add to dashboard Cite

Extracorporeal life support (ECLS), in particular veno-arterial extracorporeal membrane oxygenation, has emerged as a potentially life-saving treatment modality in patients presenting with pulmonary hypertension and right heart failure refractory to conventional treatment. Used mainly as a bridge to lung transplantation, ECLS is also being used occasionally as a bridge to recovery in patients with treatable causes of right heart failure. This review article describes indications, contraindications, techniques, and outcomes of the use of ECLS in patients with PH, focusing on practical aspects in the management of such patients.

show abstract

“…This patient showed hemodynamic improvement and was weaned from the device but died a couple of days later from gastrointestinal bleeding. 24…”

Section: Microaxial Flow Pumpsmentioning

confidence: 99%

Extracorporeal Life Support in Pulmonary Hypertension: Practical Aspects

Hoeper

2023

Semin Respir Crit Care Med

View full text Add to dashboard Cite

show abstract

“…During the follow-up, her RVAD was functioning properly, and her hemodynamic parameters improved. Another case report pertaining to the use of Impella RP (Abiomed, Danvers, MA, USA) as an assist for a 37-year-old patient with pulmonary hypertension concomitant with mixed connective tissue disease was presented by Hansen et al [ 40 ]. The Impella RP was deployed as a full assist because of profound cardiogenic shock due to acute RHF and sepsis, providing a flow rate of 4.5 L/min.…”

Section: Surgical Modalitiesmentioning

confidence: 99%

Interventional and Surgical Treatments for Pulmonary Arterial Hypertension

Stącel

Latos

Urlik

et al. 2021

JCM

View full text Add to dashboard Cite

Despite significant advancements in pharmacological treatment, interventional and surgical options are still viable treatments for patients with pulmonary arterial hypertension (PAH), particularly idiopathic PAH. Herein, we review the interventional and surgical treatments for PAH. Atrial septostomy and the Potts shunt can be useful bridging tools for lung transplantation (Ltx), which remains the final surgical treatment among patients who are refractory to any other kind of therapy. Veno-arterial extracorporeal membrane oxygenation (V-A ECMO) remains the ultimate bridging therapy for patients with severe PAH. More importantly, VA-ECMO plays a crucial role during Ltx and provides necessary left ventricular conditioning during the initial postoperative period. Pulmonary denervation may potentially be a new way to ensure better transplant-free survival among patients with the aforementioned disease. However, high-quality randomized controlled trials are needed. As established, obtaining the Eisenmenger physiology among patients with severe pulmonary hypertension by creating artificial defects is associated with improved survival. However, right-to-left shunting may be harmful after Ltx. Closure of the artificially created defects may carry some risk associated with cardiac surgery, especially among patients with Potts shunts. In conclusion, PAH requires an interdisciplinary approach using pharmacological, interventional, and surgical modalities.

show abstract

“…Besides above-mentioned causes of RVF included in the RECOVER RIGHT study, further indications for temporary right ventricular support seem appealing. Hansen et al presented a case of a patient with sepsis induced RVF on grounds of pulmonary hypertension that initially recovered after Impella® RP implantation [22]. Again, markedly improved hemodynamic parameters were reported after initiation of hemodynamic support.…”

Section: Right Ventricular Failurementioning

confidence: 99%

Peripheral Ventricular Assist Devices in Interventional Cardiology: The Impella® Micro-Axial Pump

Becher¹,

Baumann²,

Eder³

et al. 2017

Interventional Cardiology

View full text Add to dashboard Cite

Coronary artery disease (CAD) presents an ever-growing burden on health systems especially in the Western world. While percutaneous coronary intervention (PCI) is feasible in increasingly complex CAD, certain patient groups possess a high risk for major cardiac adverse events (MACE) during PCI. Poor outcome is associated with significantly depressed left ventricular function, complexity of relevant lesions, and increasing incidence of pre-existing cerebrovascular comorbidities and poor pre-interventional status. However, these risk factors also translate into a high peri-operative risk for coronary artery bypass graft (CABG) rendering some of these patients inoperable. Peripheral ventricular assist devices (pVADs) are temporarily inserted axial or centrifugal pumps that support ventricular output during PCI. The Impella® micro-axial device (Abiomed, Danvers, Massachusetts, USA) is an easily implantable pVAD that may improve patient outcome during PCI in high-risk patients (termed "protected PCI") and in patients with cardiogenic shock (CS). pVADs in general and the Impella® system in particular play important roles in interventional cardiology and its indications and use will likely expand in the future. This chapter outlines in detail the indications, applications, and future trends concerning the Impella® system. Practical advice is given on the correct implantation of the device.

show abstract

Percutaneous right ventricular assist device in sepsis due to right ventricular failure and pulmonary hypertension

Abstract: right ventricular assist device in sepsis due to right ventricular failure and pulmonary hypertension. Acta Anaesthesiologica Scandinavica 2016.

Cited by 4 publications

References 9 publications

Extracorporeal Life Support in Pulmonary Hypertension: Practical Aspects

Extracorporeal Life Support in Pulmonary Hypertension: Practical Aspects

Interventional and Surgical Treatments for Pulmonary Arterial Hypertension

Peripheral Ventricular Assist Devices in Interventional Cardiology: The Impella® Micro-Axial Pump

Contact Info

Product

Resources

About